A pioneering collaboration between Omnigene Medical Technologies Ltd and the University of Malta is developing a liquid biopsy platform that could transform how cancer is monitored. Called M3Profiler, the technology analyses tumour-derived exosomes – tiny vesicles released into the bloodstream by cancer cells – to generate detailed molecular profiles from just a small blood sample. By enabling clinicians to monitor how tumours evolve and respond to treatment over time, it aims to reduce reliance on repeated invasive biopsies while supporting more personalised care. Although still undergoing clinical validation, the proof-of-concept has shown the platform’s potential to make cancer monitoring more sensitive, less invasive and better suited to the era of precision oncology.
Cancer diagnosis has changed dramatically over the past few decades. Today, doctors can combine medical imaging, tissue biopsies, and increasingly sophisticated blood tests to understand what is happening inside a patient’s body. Yet despite these advances, one stubborn challenge remains: cancers evolve. A tumour that responds to treatment today may become resistant tomorrow, and the only way to truly understand those changes often involves invasive procedures or waiting months for follow-up scans.
A project led by Omnigene Medical Technologies Ltd in collaboration with the University of Malta believes there is a better way. The platform, M3Profiler, aims to transform an ordinary blood sample into a detailed portrait of a patient’s cancer, allowing clinicians to monitor how tumours change over time using only a few drops of blood. Rather than replacing existing diagnostics, M3Profiler seeks to fill one of oncology’s biggest blind spots: making cancer monitoring more sensitive, less invasive and better suited to the reality that every tumour is constantly evolving.
Tiny Messengers With a Big Story to Tell
The key to the technology lies in structures so small they remained unknown until relatively recently. In the context of cancer, these tumour-derived microscopic particles, known as exosomes, are continuously released by cells into the bloodstream. Far from being cellular debris, these vesicles carry fragments of their parent cells, including proteins and other molecular signatures that reveal their origin. Cancer cells release their own distinctive vesicles, effectively sending tiny packages into circulation that preserve information about the tumour itself. This makes them an attractive target for researchers. Instead of removing tissue directly from a tumour, scientists can potentially learn about the disease by analysing these circulating messengers. The challenge is that finding them is rather like trying to locate a handful of specific grains of sand on an entire beach.
Why Existing Blood Tests Still Have Limitations
Liquid biopsies are already changing cancer diagnostics by detecting fragments of tumour DNA or other biomarkers in blood samples. Compared with traditional tissue biopsies, they are less invasive and easier to repeat throughout treatment. However, they are not perfect. Many existing approaches require relatively large blood samples or struggle when tumour-derived biomarkers are present in very low concentrations, particularly during early disease or while monitoring subtle changes during treatment. Since cancers are rarely uniform, understanding how different populations of tumour cells evolve can also prove difficult.
This is precisely the gap M3Profiler is designed to address. Instead of searching broadly for every possible biomarker, the system first enriches the sample by selectively capturing tumour-derived vesicles from the far larger population of normal exosomes circulating in blood. By concentrating the information that matters most, it becomes possible to build a much richer picture from a remarkably small amount of plasma. The result is not simply earlier detection, but potentially a better understanding of how a cancer progresses, responds to therapy and, crucially, whether it begins to return.
Finding a Needle in a Molecular Haystack
Detecting tumour-derived exosomes is one of the greatest technical challenges in this field because they are vastly outnumbered by vesicles released from healthy tissues. M3Profiler approaches this problem using a carefully selected cocktail of tumour-specific antibodies. These antibodies recognise characteristic molecules on the surface of cancer-derived vesicles and bind to them, forming specialised exosome-bead complexes while leaving most normal vesicles behind.
Once isolated, researchers can analyse these complexes for a broad range of tumour markers simultaneously. According to the team, the technology successfully demonstrated that more than 12 different antigens can be measured in a single workflow without compromising analytical accuracy. This level of multiplexing is important because cancers rarely communicate through a single biomarker. Looking at many markers together provides a more complete picture than relying on just one molecular signal.
More Information From Less Blood
Perhaps one of the most striking outcomes of the proof-of-concept phase was not simply that the technology worked, but how little material it required. The researchers found that they could reliably generate detailed tumour profiles using sample volumes that conventional diagnostic platforms would often consider too small to analyse. Rather than demanding larger blood draws, M3Profiler extracts more information from less material by concentrating tumour-derived vesicles before analysis. This could become particularly valuable for patients who require repeated testing over months or years of treatment, where frequent blood collection can become burdensome. The platform also enables longitudinally, allowing clinicians to compare molecular changes over time instead of relying on occasional snapshots.
Following Cancer as it Changes
Cancer is not a static disease. Tumours evolve continuously as new genetic mutations appear and resistant cell populations emerge. This evolution often explains why treatments that initially work eventually become less effective. The researchers behind M3Profiler envision a future where these changes can be monitored through regular blood tests rather than repeated invasive biopsies.
Instead of waiting several months for imaging studies to reveal whether a treatment has succeeded, clinicians could potentially observe molecular changes much earlier. The platform also offers the possibility of tracking tumour heterogeneity by identifying the emergence of resistant clones before they become clinically obvious. Since the workflow requires only small blood samples, patients could undergo testing more frequently, making it easier to detect disease recurrence at its earliest stages. While larger clinical studies are still needed before the technology reaches hospitals, the potential shift is significant: cancer monitoring could become proactive rather than reactive.
A Multidisciplinary Effort Behind the Scenes
Although M3Profiler centres on cancer biology, its development extends far beyond biomedical research alone. The project brings together expertise in immunoassays, product engineering, manufacturing, regulatory documentation, technology transfer and diagnostic development. Translating an idea into a clinically deployable diagnostic requires not only scientific innovation but also the engineering, quality assurance and industrial partnerships needed to satisfy stringent medical device regulations.
The University of Malta plays a key role in validating the workflow using patient material, while Omnigene Medical Technologies Ltd leads the project’s overall development towards a diagnostic platform suitable for clinical use. Represented by Prof. Godfrey Grech (Department of Pathology) and Dr Laura Grech (Department of Applied Biomedical Science), the University of Malta performed an initial validation study using patient-derived blood samples. The researchers emphasise that understanding tumour biology remains one of the biggest scientific challenges. Although the platform itself is highly adaptable, identifying the surface markers that distinguish different tumour types requires ongoing research. New projects are already expanding these efforts, including work aimed at integrating RNA-based analyses to further improve treatment monitoring. Moreover, the methodology’s potential for various applications has also attracted other biotech companies to utilise it.
Building Precision Oncology in Malta
Beyond the technology itself, M3Profiler reflects something broader about Malta’s growing research ecosystem. Developing sophisticated diagnostic platforms locally shows that internationally competitive biomedical innovation does not need to happen exclusively in large research centres abroad. Instead, collaborations between academia and industry are creating specialised expertise capable of contributing to global advances in precision medicine. The team believes this strengthens Malta’s position within international oncology research while creating opportunities for future partnerships and commercial development.
Ultimately, the project’s success will be measured not by publications or patents, but by its eventual impact on patients. Cancer diagnosis and monitoring have traditionally been associated with invasive procedures, lengthy waiting periods and considerable uncertainty. M3Profiler offers a glimpse of a different future – one where a routine blood sample could reveal how a tumour is changing, whether a treatment is working and whether the disease is beginning to return.
The technology has not yet reached the clinic. Larger validation studies, regulatory approval and manufacturing scale-up still lie ahead. Yet the proof-of-concept has demonstrated that the underlying approach works, bringing the prospect of highly sensitive, minimally invasive cancer monitoring a significant step closer.
Comments are closed for this article!